Effective management for osteoporosis involves pharmacotherapeutics aimed at reducing bone resorption, enhancing bone formation, and improving bone strength. Bisphosphonates, such as alendronate and zoledronic acid, are first-line antiresorptive agents, while denosumab, a RANK ligand inhibitor, offers an alternative for patients intolerant to bisphosphonates. Anabolic agents like teriparatide and romosozumab stimulate bone formation, particularly in severe cases. Adjunct therapies include vitamin D and calcium supplementation to support bone metabolism.
Treatment decisions should be individualized based on fracture risk assessment, comorbidities, and patient-specific factors to optimize outcomes and minimize adverse effects. Regular monitoring of bone mineral density and adherence to therapy are essential for successful management. To gain detailed insights into “Osteoporosis and its…
